SATB1 in Malignant T Cells

Research output: Contribution to journalArticle

Standard

SATB1 in Malignant T Cells. / Fredholm, Simon; Willerslev-Olsen, Andreas; Met, Özcan; Kubat, Linda; Gluud, Maria; Mathiasen, Sarah L.; Friese, Christina; Blümel, Edda; Petersen, David L.; Hu, Tengpeng; Nastasi, Claudia; Lindahl, Lise M.; Buus, Terkild B.; Krejsgaard, Thorbjørn; Wasik, Mariusz A.; Kopp, Katharina L.; Koralov, Sergei B.; Persson, Jenny L.; Bonefeld, Charlotte M.; Geisler, Carsten; Woetmann, Anders; Iversen, Lars; Becker, Jürgen C.; Ødum, Niels.

In: Journal of Investigative Dermatology, Vol. 138, No. 8, 2018, p. 1805-1815.

Research output: Contribution to journalArticle

Harvard

Fredholm, S, Willerslev-Olsen, A, Met, Ö, Kubat, L, Gluud, M, Mathiasen, SL, Friese, C, Blümel, E, Petersen, DL, Hu, T, Nastasi, C, Lindahl, LM, Buus, TB, Krejsgaard, T, Wasik, MA, Kopp, KL, Koralov, SB, Persson, JL, Bonefeld, CM, Geisler, C, Woetmann, A, Iversen, L, Becker, JC & Ødum, N 2018, 'SATB1 in Malignant T Cells', Journal of Investigative Dermatology, vol. 138, no. 8, pp. 1805-1815. https://doi.org/10.1016/j.jid.2018.03.1526

APA

Fredholm, S., Willerslev-Olsen, A., Met, Ö., Kubat, L., Gluud, M., Mathiasen, S. L., ... Ødum, N. (2018). SATB1 in Malignant T Cells. Journal of Investigative Dermatology, 138(8), 1805-1815. https://doi.org/10.1016/j.jid.2018.03.1526

CBE

Fredholm S, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL, Friese C, Blümel E, Petersen DL, Hu T, Nastasi C, Lindahl LM, Buus TB, Krejsgaard T, Wasik MA, Kopp KL, Koralov SB, Persson JL, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Becker JC, Ødum N. 2018. SATB1 in Malignant T Cells. Journal of Investigative Dermatology. 138(8):1805-1815. https://doi.org/10.1016/j.jid.2018.03.1526

MLA

Vancouver

Fredholm S, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL et al. SATB1 in Malignant T Cells. Journal of Investigative Dermatology. 2018;138(8):1805-1815. https://doi.org/10.1016/j.jid.2018.03.1526

Author

Fredholm, Simon ; Willerslev-Olsen, Andreas ; Met, Özcan ; Kubat, Linda ; Gluud, Maria ; Mathiasen, Sarah L. ; Friese, Christina ; Blümel, Edda ; Petersen, David L. ; Hu, Tengpeng ; Nastasi, Claudia ; Lindahl, Lise M. ; Buus, Terkild B. ; Krejsgaard, Thorbjørn ; Wasik, Mariusz A. ; Kopp, Katharina L. ; Koralov, Sergei B. ; Persson, Jenny L. ; Bonefeld, Charlotte M. ; Geisler, Carsten ; Woetmann, Anders ; Iversen, Lars ; Becker, Jürgen C. ; Ødum, Niels. / SATB1 in Malignant T Cells. In: Journal of Investigative Dermatology. 2018 ; Vol. 138, No. 8. pp. 1805-1815.

RIS

TY - JOUR

T1 - SATB1 in Malignant T Cells

AU - Fredholm, Simon

AU - Willerslev-Olsen, Andreas

AU - Met, Özcan

AU - Kubat, Linda

AU - Gluud, Maria

AU - Mathiasen, Sarah L.

AU - Friese, Christina

AU - Blümel, Edda

AU - Petersen, David L.

AU - Hu, Tengpeng

AU - Nastasi, Claudia

AU - Lindahl, Lise M.

AU - Buus, Terkild B.

AU - Krejsgaard, Thorbjørn

AU - Wasik, Mariusz A.

AU - Kopp, Katharina L.

AU - Koralov, Sergei B.

AU - Persson, Jenny L.

AU - Bonefeld, Charlotte M.

AU - Geisler, Carsten

AU - Woetmann, Anders

AU - Iversen, Lars

AU - Becker, Jürgen C.

AU - Ødum, Niels

PY - 2018

Y1 - 2018

N2 - Deficient expression of SATB1 hampers thymocyte development and results in inept T-cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides, the most frequent variant of cutaneous T-cell lymphoma. Here, we report on a disease stage-associated decrease of SATB1 expression and an inverse expression of STAT5 and SATB1 in situ. STAT5 inhibited SATB1 expression through induction of microRNA-155. Decreased SATB1 expression triggered enhanced expression of IL-5 and IL-9 (but not IL-6 and IL-32), whereas increased SATB1 expression had the opposite effect, indicating that the microRNA-155 target SATB1 is a repressor of IL-5 and IL-9 in malignant T cells. In accordance, inhibition of STAT5 and its upstream activator JAK3 triggered increased SATB1 expression and a concomitant suppression of IL-5 and IL-9 expression in malignant T cells. In conclusion, we provide a mechanistic link between the proto-oncogenic JAK3/STAT5/microRNA-155 pathway, SATB1, and cytokines linked to CTCL severity and progression, indicating that SATB1 dysregulation is involved in cutaneous T-cell lymphoma pathogenesis.

AB - Deficient expression of SATB1 hampers thymocyte development and results in inept T-cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides, the most frequent variant of cutaneous T-cell lymphoma. Here, we report on a disease stage-associated decrease of SATB1 expression and an inverse expression of STAT5 and SATB1 in situ. STAT5 inhibited SATB1 expression through induction of microRNA-155. Decreased SATB1 expression triggered enhanced expression of IL-5 and IL-9 (but not IL-6 and IL-32), whereas increased SATB1 expression had the opposite effect, indicating that the microRNA-155 target SATB1 is a repressor of IL-5 and IL-9 in malignant T cells. In accordance, inhibition of STAT5 and its upstream activator JAK3 triggered increased SATB1 expression and a concomitant suppression of IL-5 and IL-9 expression in malignant T cells. In conclusion, we provide a mechanistic link between the proto-oncogenic JAK3/STAT5/microRNA-155 pathway, SATB1, and cytokines linked to CTCL severity and progression, indicating that SATB1 dysregulation is involved in cutaneous T-cell lymphoma pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85048705717&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2018.03.1526

DO - 10.1016/j.jid.2018.03.1526

M3 - Article

VL - 138

SP - 1805

EP - 1815

JO - Advances in biology of skin

T2 - Advances in biology of skin

JF - Advances in biology of skin

SN - 1523-1747

IS - 8

ER -